http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110845601-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-31 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-605 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-605 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-26 |
| filingDate | 2019-11-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-01-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-01-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-110845601-B |
| titleOfInvention | Application of GLP-1-like peptide-modified dimers with different configurations and their preparation methods in the treatment of type II diabetes |
| abstract | The present invention provides the application of novel glucagon peptide 1 fatty acid modified or non-modified dimers with different configurations for pancreatic protection or hypoglycemic effect in the treatment of II diabetes. The dimer of the present invention is formed by connecting two identical cysteine-containing GLP-1 monomers through a disulfide bond formed by cysteine oxidation. The H-type GLP-1 homodimer of the present invention (which forms a disulfide bond inside the peptide chain) significantly increases the glucose-lowering duration of the GLP-1 dimer without reducing the activity, and the provided GLP-1 is similar The continuous activity of the dimer in vivo is up to 19 days, which is significantly longer than that of the positive control drug liraglutide, which is 3 days, or compared with the long-acting GLP1-like peptides that have been reported so far, which greatly promotes long-term growth. The technical progress of GLP1 drugs and the convenience of their clinical application and promotion. At the same time, the U-type homodimer (disulfide bond formed at the C-terminus of the peptide chain) does not affect blood sugar, but can significantly protect exocrine cells such as pancreatic acinar and duct, and protect the function of the pancreas. |
| priorityDate | 2019-10-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 299.